ClinicalTrials.gg
CompletedNCT05069896Updated Mar 4, 2025Results posted

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

A Phase 1 interventional study of Mirikizumab Prefilled Syringe and Mirikizumab Autoinjector in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated.

Screening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or non-pregnant females of childbearing or non-
  • Have (BMI) within the range 18.0 to 32.0 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Must not show evidence of active or latent tuberculosis (TB)
  • Must not have received (s) (including attenuated live vaccines and those administered intranasally) within 8 weeks of screening, or intend to during the study
  • Must not have been treated with within 1 month of screening, or intend to during the study
  • Must not have had a serious infection, or have been hospitalized or have received IV antibiotics for an infection within 12 weeks prior to Day 1
  • Must not be
  • Must not have received treatment with biologic agents (e.g. monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to Day 1
  • Must not have multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment reactions
  • Must not have had lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Must not have had breast cancer within the past 10 years
  • Must not have significant allergies to humanized monoclonal antibodies
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
237 participants (actual)

Study arms

  • Experimental
    Mirikizumab - Prefilled Syringe

    Participants received 3 milliliter (mL) mirikizumab as 2 subcutaneous (SC) injections of 1 mL and 2 mL delivered via a prefilled syringe (PFS) to abdomen or arms or thighs.

    Drug: Mirikizumab Prefilled Syringe

  • Experimental
    Mirikizumab - Autoinjector

    Participants received 3 mL mirikizumab as 2 SC injections of 1 mL and 2 mL delivered an autoinjector (AI) to abdomen or arms or thighs.

    Drug: Mirikizumab Autoinjector

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AI

    PK: Cmax of Mirikizumab administered by PFS and AI.

    Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose

  2. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab Administered by PFS and AI

    PK: AUC\[0-∞\] of Mirikizumab administered by PFS and AI.

    Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose

  3. PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab Administered by PFS and AI

    PK: AUC\[0-tlast\] of Mirikizumab administered by PFS and AI.

    Time frame: Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose

07

Results

Posted Mar 4, 2025

Participant flow

Participant flow — Overall Study
MilestoneMirikizumab Pre-filled Syringe (PFS) - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab Autoinjector (AI) - AbdomenMirikizumab AI - ArmMirikizumab AI - Thigh
Started393939404040
Received at least one dose of study drug393939404040
Completed393837403938
Not completed012012
Withdrew: Adverse event011000
Withdrew: Lost to follow-up001012

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AI

PK: Cmax of Mirikizumab administered by PFS and AI.

Time frame:
Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AI
micrograms per milliliter (μg/mL)Mirikizumab PFSMirikizumab AI
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab Administered by PFS and AI20.0 ± 4423.5 ± 40
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab Administered by PFS and AI

PK: AUC\[0-∞\] of Mirikizumab administered by PFS and AI.

Time frame:
Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab Administered by PFS and AI
microgram*day per milliliter (μg*day/mL)Mirikizumab PFSMirikizumab AI
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Mirikizumab Administered by PFS and AI359 ± 44412 ± 39
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab Administered by PFS and AI

PK: AUC\[0-tlast\] of Mirikizumab administered by PFS and AI.

Time frame:
Pre-dose, 72, 120, 192, 264, 360, 528, 696, 1032, 1368, 1704, 2040 hours post day 1 dose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab Administered by PFS and AI
microgram*day per milliliter (μg*day/mL)Mirikizumab PFSMirikizumab AI
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Mirikizumab Administered by PFS and AI355 ± 44411 ± 38

Adverse events

Collected over Baseline up to 88 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirikizumab PFS - Abdomen0/39 (0%)0/39 (0%)8/39 (20.5%)
Mirikizumab PFS - Arm0/39 (0%)0/39 (0%)13/39 (33.3%)
Mirikizumab PFS - Thigh0/39 (0%)0/39 (0%)8/39 (20.5%)
Mirikizumab AI - Abdomen0/40 (0%)1/40 (2.5%)13/40 (32.5%)
Mirikizumab AI - Arm0/40 (0%)0/40 (0%)9/40 (22.5%)
Mirikizumab AI - Thigh0/40 (0%)0/40 (0%)9/40 (22.5%)
Most frequent serious events
Most frequent serious events
EventMirikizumab PFS - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab AI - AbdomenMirikizumab AI - ArmMirikizumab AI - Thigh
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/190/250/221/210/290/22
Most frequent other events
Showing 10 of 14
Most frequent other events
EventMirikizumab PFS - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab AI - AbdomenMirikizumab AI - ArmMirikizumab AI - Thigh
HeadacheNervous system disorders4/396/392/391/403/404/40
Injection site reactionGeneral disorders0/391/391/396/405/401/40
COVID-19Infections and infestations1/393/393/394/404/402/40
CoughRespiratory, thoracic and mediastinal disorders0/393/390/391/401/402/40
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/393/390/391/400/400/40
Nasal congestionRespiratory, thoracic and mediastinal disorders0/392/390/390/401/403/40
DiarrhoeaGastrointestinal disorders1/392/390/392/401/400/40
NauseaGastrointestinal disorders0/392/392/391/401/400/40
VomitingGastrointestinal disorders2/391/390/390/401/401/40
FatigueGeneral disorders0/390/392/390/401/401/40

Baseline characteristics

All participants who received at least one dose of mirikizumab.

Age, Continuous
Age, Continuous(years)Mirikizumab PFS - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab AI - AbdomenMirikizumab AI - ArmMirikizumab AI - ThighTotal
Mean42.7 ± 12.739.2 ± 11.642.5 ± 13.242.1 ± 14.442.6 ± 13.039.1 ± 12.841.3 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Mirikizumab PFS - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab AI - AbdomenMirikizumab AI - ArmMirikizumab AI - ThighTotal
Female192522212922138
Male20141719111899
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mirikizumab PFS - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab AI - AbdomenMirikizumab AI - ArmMirikizumab AI - ThighTotal
Hispanic or Latino641389848
Not Hispanic or Latino333526323132189
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mirikizumab PFS - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab AI - AbdomenMirikizumab AI - ArmMirikizumab AI - ThighTotal
American Indian or Alaska Native0000000
Asian2100317
Native Hawaiian or Other Pacific Islander0000000
Black or African American45548329
White323333352936198
More than one race1011003
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Mirikizumab PFS - AbdomenMirikizumab PFS - ArmMirikizumab PFS - ThighMirikizumab AI - AbdomenMirikizumab AI - ArmMirikizumab AI - ThighTotal
United States393939404040237
08

Study locations

3 sites
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • QPS
    Springfield, Missouri 65802, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jun 2022, 8 months.

Results were first posted in Mar 2025, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2021
First posted
Oct 6, 2021
StartActual
Oct 5, 2021
Primary completionActual
Jun 22, 2022
CompletionActual
Jun 22, 2022
Results first posted
Mar 4, 2025
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05069896
Responsible party
Sponsor
First posted
Oct 6, 2021
Start date
Oct 5, 2021
Primary completion
Jun 22, 2022
Completion
Jun 22, 2022
Results posted
Mar 4, 2025
Last update
Mar 4, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion